Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Equity Forum 2015
20 slides from Aap Implantate's conference presentation, Nov 24, 2015
Slide 1: aap Implantate AG – German Equity Forum 2015
aap Implantate AG Corporate Presentation German Equity Forum 2015 Frankfurt am Main, November 24, 2015 Bruke Seyoum Alemu, CEO Marek Hahn, CFO
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap Company Overview
aap Company Overview • German based international MedTech company • Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ.DE) • 2014: Sales EUR 30.6 million*, EBITDA (norm.) EUR 1.4 million** • Operating with two Centres of Excellence Center of Excellence Trauma, Berlin Center of Excellence Bioma
Slide 4: aap Trauma – LOQTEQ® Product Line
aap Trauma – LOQTEQ® Product Line Concept Application Protected by several global patents Mainstream trauma, lower & upper extremities Competitive Environment Entirely benchmarked against the market leader Synthes Stryker Zimmer S&N Königsee aap 4
Slide 5: aap Trauma – LOQTEQ® Product Line
aap Trauma – LOQTEQ® Product Line Portfolio Growth Track Record Comprehensive and procedure focused Driven by BRICS, SMIT and Europe LOQTEQ® sales in EUR million 9 8 7 6 5 4 8.2 3 5.0 2 1 0.4 1.8 0 2011 2012 2013 2014 Value • Genuine alternative to the gold standard with new and additional features
Slide 6: aap Trauma – LOQTEQ® Development
aap Trauma – LOQTEQ® Development 6
Slide 7: aap Silver Coating – Value-based innovation
aap Silver Coating – Value-based innovation Unmet Need Innovative Solution Infection prevention for medical devices Surgical Site Infection (SSI) ✓ Prevention of bacterial colonization ✓ Platform technology with broad application Biofilm formed on an TiAl6V4 ✓ Very high efficacy (in vitro / in vivo)
Slide 8: aap Silver Coating – Benchmarking
aap Silver Coating – Benchmarking* aap Market Leader 1 Market Leader 2 Antibacterial agent micro-Ag / nano-Ag AgNO3 micro-Ag / nano-Ag Coating principle Single step: 4-step in 2 solutions: Multi-step: Electrochemical (PEO) Electrochemical (acidic anodization) & vacuum deposition dipping Antibacteria
Slide 9: aap Silver Coating – Regulatory Path
aap Silver Coating – Regulatory Path Results delivered Regulatory Path Comprehensive animal trials accomplished to a large extent Short term targeted CE- and FDA-clearance Biocompatibility Efficacy Cytotoxicity In-vitro Ex-vivo CE CE Approval FDAFDA Approval Irritation Pin implant infection Submit p
Slide 10: aap's Aspiration and Imperatives
aap’s Aspiration and Imperatives MISSION Making trauma treatment better and cost-effective VISION Become a leading European trauma company STRATEGIC IMPERATIVES Products Customers Distribution Services Accelerating value-based Enhancing market access innovation Getting focused on Trauma Geography Co
Slide 11: Implementation of Strategic Imperatives – Progress in 2015
Implementation of Strategic Imperatives Progress in 2015 Products Customers Accelerating Value-based Innovation Enhancing Market Access LOQTEQ®: portfolio extension toward full range main Headwind in BRICS and SMIT countries Services stream trauma (>90% indication coverage) Experienced sales l
Slide 12: Outlook 2015
Outlook 2015 • Updated Outlook 2015: – Sales: EUR 27.5 million – EUR 31.5 million – EBITDA: EUR -1.5 million – EUR 1.0 million • Transformation of aap Implantate AG into a focused trauma company remains core objective of our strategic direction 12
Slide 13: Implementation of Strategic Imperatives – Getting focused on Trauma
Implementation of Strategic Imperatives Getting focused on Trauma Focus on core business aap’s Silver Technology applied in 2008 2009 2010 2011 2012 2013 2014 2015 Orthopedics, Cardiology, Dental Dental + and surgical instruments Analytics + + Medical Aesthetics + + Recon + + + + + Inflection Contra
Slide 14: aap – Sum of the Parts
aap – Sum of the Parts aap Trauma aap Silver Technology addresses unmet need of the industry Strong sales growth in the first three years after (infection prevention) launch 2012-2014; CAGR 2011-2014: 174% Strong IP, platform technology with a wide range of Strong IP, comprehensive portfolio
Slide 15: The New aap – 2016 and beyond
The New aap – 2016 and beyond Completely transformed business DIFFERENTIATION GROWTH OUR GOALS aap with a unique position aap with multiple drivers for aap with a sound strategy to create and opportunity for future delivering profitable growth value growth Continuous new product Focused on most attr
Slide 16: Contact
Contact aap Implantate AG Lorenzweg 5 12099 Berlin Fabian Franke Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de Website: www.aap.de IR-app: 16
Slide 17: Appendix
Appendix 17
Slide 18: Highlights FY/2014 – Financial Figures
Highlights FY/2014 – Financial Figures (in EUR million) FY/2014* FY/2013 Change Sales 30.6 28.6 7% Trauma 12.2 9.6 27% of which LOQTEQ® 8.2 5.0 63% Biomaterials 16.4 15.0 10% Projects 1.2 2.8 -58% Other 0.8 1.2 -31% FY/2014* FY/2013 Change EBITDA 2.3 5.1 -55% of which projects 0.8 4.4 -82% of which
Slide 19: Highlights 9M/2015 – Financial Figures
Highlights 9M/2015 – Financial Figures (in EUR million) 9M/2015* 9M/2014 Change Sales 22.0 22.1 0% Trauma 8.5 8.4 1% of which LOQTEQ® 5.2 5.3 -2% Biomaterials 13.0 12.7 2% Projects 0.2 0.3 -25% Other 0.3 0.7 -59% 9M/2015* 9M/2014 Change EBITDA -0.3 2.4 < -100% of which projects 0.2 0.0 > +100% of wh
Slide 20: Shareholder structure
Shareholder structure • Growing interest in aap´s value driving strategy is also reflected in new shareholders: – December 2013: Taaleritehdas ArvoRein Equity Fund, Finland – March 2014: Ennismore Fund Management Limited, UK – April 2014: Fidelity Funds SICAV, Luxembourg – January 2015: Ratio Capita